Nanoparticle-mediated synergistic drug combination for treating bone metastasis
Journal of Controlled Release · 2023-05 · 357 · 498-510
DOI: 10.1016/j.jconrel.2023.04.019 ↗Kurz gefasst
Fachartikel in der Zeitschrift Journal of Controlled Release, 2023-05. Verfasst von Mohammed Tanjimur Rahman und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Hauptthemen laut MEDLINE: Bone Neoplasms, Bone Resorption, Nanoparticles. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 54 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NIH HHS, NCRR NIH HHS.
Abstract (Originalsprache)
Bone metastasis at an advanced disease stage is common in most solid tumors and is untreatable. Overexpression of receptor activator of nuclear factor κB ligand (RANKL) in tumor-bone marrow microenvironment drives a vicious cycle of tumor progression and bone resorption. Biodegradable nanoparticles (NPs), designed to localize in the tumor tissue in bone marrow, were evaluated in a prostate cancer model of bone metastasis. The combination treatment, encapsulating docetaxel, an anticancer drug (TXT-NPs), and Denosumab, a monoclonal antibody that binds to RANKL (DNmb-NPs), administered intravenously regressed the tumor completely, preventing bone resorption, without causing any mortality. With TXT-NPs alone treatment, after an initial regression, the tumor relapsed and acquired resistance, whereas DNmb-NPs alone treatment was ineffective. Only in the combination treatment, RANKL was not detected in the tumor tibia, thus negating its role in tumor progression and bone resorption. The combination treatment was determined to be safe as the vital organ tissue showed no increase in inflammatory cytokine or the liver ALT/AST levels, and animals gained weight. Overall, dual drug treatment acted synergistically to modulate the tumor-bone microenvironment with encapsulation enhancing their therapeutic potency to achieve tumor regression.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Small Animal Imaging Core, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Genitourinary Malignancies Research Center, Department of Cancer Biology, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA.
- Department of Biomedical Engineering, Lerner Research Institute, Cleveland Clinic, Cleveland, OH 44195, USA. Electronic address: labhasv@ccf.org.
Förderung
- NCI NIH HHS
- NIH HHS
- NCRR NIH HHS
Zitieren
APA
Rahman, M. T., Kaung, Y., Shannon, L., Androjna, C., Sharifi, N., & Labhasetwar, V. (2023). Nanoparticle-mediated synergistic drug combination for treating bone metastasis. Journal of Controlled Release, 357, 498-510. https://doi.org/10.1016/j.jconrel.2023.04.019
Vancouver
Rahman MT, Kaung Y, Shannon L, Androjna C, Sharifi N, Labhasetwar V. Nanoparticle-mediated synergistic drug combination for treating bone metastasis. Journal of Controlled Release. 2023;357:498-510. doi:10.1016/j.jconrel.2023.04.019
BibTeX
@article{Rahman2023,
author = {Rahman, Mohammed Tanjimur and Kaung, Youzhi and Shannon, Logan and Androjna, Charlie and Sharifi, Nima and Labhasetwar, Vinod},
title = {Nanoparticle-mediated synergistic drug combination for treating bone metastasis},
journal = {Journal of Controlled Release},
year = {2023},
volume = {357},
pages = {498--510},
doi = {10.1016/j.jconrel.2023.04.019}
}
EUVIMED